Gritstone Bio shares are trading higher after the company announced the SARS-CoV-2 T cell epitopes administered within its self-amplifying mRNA COVID-19 vaccines are minimally impacted by the omicron variant.

by | Nov 30, 2021 | Extra Jobs | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.